Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Date:9/14/2007

CRANBURY, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today results for its fourth quarter and fiscal year ended June 30, 2007. Palatin reported a net loss of $6.1 million, or ($0.07) per basic and diluted share, for the quarter ended June 30, 2007, compared to a net loss of $7.9 million, or ($0.11) per basic and diluted share, for the same period in 2006. Total revenues in the quarter ended June 30, 2007 were $2.6 million, compared to $5.0 million for the same period in 2006. As of June 30, 2007, the Company had cash, cash equivalents and investments totaling $33.8 million.

The decrease in the net loss for the quarter ended June 30, 2007 versus the quarter ended June 30, 2006 was primarily attributable to decreased research and development spending on bremelanotide, the Company's drug under development for the treatment of erectile dysfunction (ED) and female sexual dysfunction (FSD). Cost reimbursement revenue from King Pharmaceuticals, Inc. (King) also decreased as a result of the lower spending.

For the years ended June 30, 2007 and 2006, total revenues were $14.4 million and $19.7 million, respectively. Palatin's net loss for the year ended June 30, 2007 was $27.8 million, or ($0.36) per basic and diluted share, compared to a net loss of $29.0 million, or ($0.48) per basic and diluted share, for the year ended June 30, 2006.

FISCAL YEAR 2007 AND RECENT DEVELOPMENTS

Significant developments in Palatin's business since June 30, 2006 include the following:

-- The announcement of results of Part 2 of a Phase 2A pilot study

evaluating the effects of bremelanotide in post-menopausal women

diagnosed with FSD in which subjects re
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Due to a misstatement posted by the Family ... Technology Center, LLC ( ASCTC ) was reported as an ... might benefit ALS patients. Because of ASCTC's exclusive focus ... and therapeutic applications, FRC listed ASCTC as one of several ... wish not to support research that requires the death of ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... ... and dietary supplement products with strong scientific roots and clinical support for burgeoning markets ... North Brunswick, ... at the crossroads of foods and pharmaceuticals, and RFI Ingredients, a manufacturer of innovative ...
... of death from roadside bombs to freeway crashes. Traumatic injury, ... 44, often overwhelms the body,s natural blood-clotting process. In ... by Erin Lavik, a new Case Western Reserve University biomedical ... built synthetic platelets that show promise in halting internal and ...
... ... , ... (Vocus) December 16, 2009 -- Scientists at the U.S. Department of Energy’s (DOE) Argonne ... microgears when suspended in a solution, providing insights for design of bio-inspired dynamically adaptive ...
Cached Biology Technology:WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 2WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 3Researchers take the inside route to halt bleeding 2Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3
(Date:8/28/2014)... is available in German . ... owes its name to a striking pattern of blue stripes ... cells, reflective silvery cells, and yellow cells emerge during growth ... as a multilayered mosaic to compose the characteristic colour pattern. ... types have to interact to form proper stripes, the embryonic ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
Breaking Biology News(10 mins):How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3UMN researchers find animal model for understudied type of muscular dystrophy 2
... FAIRFAX, Va.For the first time, the Society of ... professional articles about uterine artery embolization, a treatment directed ... adverse health effects that may occur due to the ... and Interventional Radiology "virtual" collection allows health care ...
... Conservation Society announced today that critically endangered alligators in ... WCS,s Bronx Zoo, in partnership with two other North ... Management of the State Forestry Administration of China, has ... multiplying on their own. The alligator hatchlings15 in ...
... is the foundation of the body,s immune response and ... is part of the immune system, and recognizes certain ... HIV. How the molecule binds to pathogens has been ... by University of Illinois chemist Deborah Leckband show that ...
Cached Biology News:Avoiding hysterectomy: Major interventional radiology E-collection info available 2Avoiding hysterectomy: Major interventional radiology E-collection info available 3Reintroduced Chinese alligators now multiplying in the wild in China 2Reintroduced Chinese alligators now multiplying in the wild in China 3Flexible neck in cell-receptor DC-SIGN targets more pathogens 2
... of glass plates, bar clamp, and a ... of these units are:, safety interlock lids ... , upper and lower reservoirs have drains ... disposal of buffer solutions , leveling base ...
... is a cytochrome P450 (CYP450) metabolite postulated ... renal and cerebral vasculature. In rat cerebral ... pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted mainly ... free 20-HETE (20-40 pg/ml in human urine) ...
... kits are designed to rapidly and reliably ... patented APA Technology. APAgene provides hassle-free, ready-to ... All necessary ingredients are provided in each ... used for gap filling, localized cloning of ...
... APAgene kits are designed to ... DNA using our patented APA ... components, at an extraordinarily competitive price. ... each kit. The Locator Kit can ...
Biology Products: